Denosumab (Prolia) has emerged as a promising therapeutic intervention for osteoporosis due to its ability to inhibit bone resorption by decreasing RANKL-induced osteoclast activity (Hanley et al., 2012). This evidence concerns the gene TNFSF11 and osteoporosis.